Russell Investments Group Ltd. Purchases 152,837 Shares of Janux Therapeutics, Inc. $JANX

Key Points

• Russell Investments Group Ltd. significantly increased its stake in Janux Therapeutics by 15,117.4%, acquiring 152,837 additional shares, bringing its total ownership to 153,848 shares valued at approximately $4.15 million.
• Analysts show strong confidence in Janux Therapeutics, with two firms rating the stock as a Strong Buy and an average price target of $86.90, amid expectations that the company will report negative earnings per share this year.
• Janux Therapeutics has a current stock price of $24.30, with a market capitalization of $1.46 billion, experiencing a 1.3% increase in trading on the latest report day.

Russell Investments Group Ltd. raised its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 15,117.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 153,848 shares of the company's stock after buying an additional 152,837 shares during the quarter. Russell Investments Group Ltd. owned 0.26% of Janux Therapeutics worth $4,154,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. RA Capital Management L.P. increased its stake in Janux Therapeutics by 13.1% in the 4th quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company's stock valued at $554,977,000 after buying an additional 1,200,000 shares during the period. Janus Henderson Group PLC increased its stake in Janux Therapeutics by 41.2% in the 4th quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company's stock valued at $190,617,000 after buying an additional 1,038,996 shares during the period. Paradigm Biocapital Advisors LP increased its stake in Janux Therapeutics by 46.5% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock valued at $188,246,000 after buying an additional 1,115,412 shares during the period. Vanguard Group Inc. increased its stake in Janux Therapeutics by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 2,278,660 shares of the company's stock valued at $61,524,000 after buying an additional 142,328 shares during the period. Finally, Woodline Partners LP increased its stake in Janux Therapeutics by 15.7% in the 4th quarter. Woodline Partners LP now owns 1,852,187 shares of the company's stock valued at $99,166,000 after buying an additional 251,924 shares during the period. Institutional investors and hedge funds own 75.39% of the company's stock.

Janux Therapeutics Stock Down 1.3%

Shares of JANX traded down $0.30 during mid-day trading on Thursday, hitting $23.05. 456,373 shares of the company's stock were exchanged, compared to its average volume of 838,502. The firm has a fifty day moving average of $24.53 and a two-hundred day moving average of $27.31. Janux Therapeutics, Inc. has a twelve month low of $21.97 and a twelve month high of $71.71. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of -12.81 and a beta of 2.86.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.07). On average, equities analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on JANX. Raymond James Financial began coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They issued an "outperform" rating and a $65.00 price objective on the stock. Piper Sandler assumed coverage on shares of Janux Therapeutics in a research note on Monday, August 18th. They set an "overweight" rating and a $42.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $86.90.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.